1N7 Stock Overview A medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Nevro Historical stock prices Current Share Price US$3.54 52 Week High US$18.90 52 Week Low US$3.40 Beta 0.83 1 Month Change -11.50% 3 Month Change -19.55% 1 Year Change -79.66% 3 Year Change -95.31% 5 Year Change -96.66% Change since IPO -82.43%
Recent News & Updates
Nevro Corp. Announces the Publication of New Data in Medical Devices Nov 19
Third quarter 2024 earnings released: US$0.41 loss per share (vs US$0.65 loss in 3Q 2023) Nov 12
Nevro Corp. Reaffirms Earnings Guidance for the Year 2024 Nov 12
Nevro Corp. Announces New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy Oct 30
Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024 Oct 11
Second quarter 2024 earnings released: US$0.53 loss per share (vs US$0.69 loss in 2Q 2023) Aug 07 See more updates
Nevro Corp. Announces the Publication of New Data in Medical Devices Nov 19
Third quarter 2024 earnings released: US$0.41 loss per share (vs US$0.65 loss in 3Q 2023) Nov 12
Nevro Corp. Reaffirms Earnings Guidance for the Year 2024 Nov 12
Nevro Corp. Announces New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy Oct 30
Nevro Corp. to Report Q3, 2024 Results on Nov 11, 2024 Oct 11
Second quarter 2024 earnings released: US$0.53 loss per share (vs US$0.69 loss in 2Q 2023) Aug 07 Nevro Revises Earnings Guidance for the Full Year 2024
Nevro Corp. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
First quarter 2024 earnings released: US$0.70 loss per share (vs US$0.98 loss in 1Q 2023) May 08
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024 May 08
Nevro Corp. to Report Q1, 2024 Results on May 07, 2024 Apr 19
New minor risk - Shareholder dilution Apr 14
Nevro Corp., Annual General Meeting, May 23, 2024 Apr 13
Full year 2023 earnings released: US$2.56 loss per share (vs US$0.085 profit in FY 2022) Feb 22 Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024
Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024 Jan 30
Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain Nov 21
Nevro Corp. Increases Revenue Guidance for the Full-Year 2023 Nov 04 Nevro Corp. Provides Revenue Guidance for the Fourth Quarter of 2023
Third quarter 2023 earnings released: US$0.65 loss per share (vs US$2.30 profit in 3Q 2022) Nov 02
New major risk - Revenue and earnings growth Oct 16
Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023 Oct 05
Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy Aug 17
Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system Aug 11 Nevro Corp. Revises Earnings Guidance for the Full-Year 2023
New minor risk - Shareholder dilution Aug 04
Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.71 loss in 2Q 2022) Aug 02
Independent Director recently bought €160k worth of stock Jun 14
Nevro Corp. Announces Executive Changes Jun 07
Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023 Jun 06
First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.98 loss in 1Q 2022) Apr 28
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023 Feb 18
Full year 2022 earnings released: EPS: US$0.085 (vs US$3.77 loss in FY 2021) Feb 18
Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting Jan 13 Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023
Third quarter 2022 earnings released: EPS: US$2.30 (vs US$1.44 loss in 3Q 2021) Nov 03
Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022 Nov 03
Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain Oct 13
Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022 Oct 06
Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy Oct 04
Nevro Corp. Announces Executive Changes Sep 10
Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy Sep 02
Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.62 loss in 2Q 2021) Aug 04 Nevro Corp. Revises Earnings Guidance for the Full Year 2022
Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations Aug 02
Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022 Jul 07
Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial Jul 06
General Counsel recently bought €95k worth of stock May 12
First quarter 2022 earnings released: US$0.98 loss per share (vs US$0.85 loss in 1Q 2021) May 06
Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earnings Guidance for the Year 2022 May 05 Nevro Corp., Annual General Meeting, May 26, 2022
Nevro Corp. to Report Q1, 2022 Results on May 04, 2022 Apr 07
Chairman of the Board recently bought €187k worth of stock Mar 10
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2022 Feb 24
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Nevro Announces Publication of Twelve Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine Feb 12
Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP) Jan 20
Nevro Corp. Announces Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy Jan 19
Nevro Corp. Announces Unitedhealthcare Coverage for High-Frequency 10 KHZ Therapy for the Treatment of Painful Diabetic Neuropathy Jan 05
Independent Director recently bought €178k worth of stock Dec 22
Nevro Corp. Announces Settlement of IP Litigation with Nalu Medical Dec 22
Nevro Corp. Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy Nov 30
General Counsel recently bought €176k worth of stock Nov 17
Third quarter 2021 earnings released: US$1.44 loss per share (vs US$0.29 loss in 3Q 2020) Nov 09
High number of new directors Nov 04 Nevro Corp. Withdraws Full Year 2021 Guidance
Second quarter 2021 earnings released: US$0.62 loss per share (vs US$1.21 loss in 2Q 2020) Aug 05 Nevro Corp. Provides Preliminary, Unaudited Revenue Guidance for the Second Quarter of 2021 Nevro Corp. SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021 and Full Year 2021 May 07
First quarter 2021 earnings released: US$0.85 loss per share (vs US$0.78 loss in 1Q 2020) May 07
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021 May 06
Nevro Introduces HFX, New Comprehensive Brand Identity Combining Nevro's Innovative Technologies, Advanced Therapies and End-To-End Patient Support Apr 27
New 90-day low: €130 Mar 07
Full year 2020 earnings released: US$2.47 loss per share (vs US$3.37 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
New 90-day high: €151 Feb 11
Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting Jan 15
Nevro Corp. to Report Q4, 2020 Results on Feb 24, 2021 Jan 12
Nevro Corp. Announces FDA Submission for HF10 Therapy Dec 30
New 90-day high: €147 Dec 22
Nevro Corp. Announces to Appoint Susan E. Siegel as a Member of the Board of Directors Dec 04
Nevro Corp. Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications Dec 01
New 90-day high: €143 Nov 11
Third quarter 2020 earnings released: US$0.29 loss per share Nov 07 Shareholder Returns 1N7 DE Medical Equipment DE Market 7D -1.1% -1.5% 0.7% 1Y -79.7% -7.0% 8.4%
See full shareholder returns
Return vs Market: 1N7 underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is 1N7's price volatile compared to industry and market? 1N7 volatility 1N7 Average Weekly Movement 13.8% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1N7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1N7's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Founded Employees CEO Website 2006 1,215 Kevin Thornal nevro.com
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands.
Show more Nevro Corp. Fundamentals Summary How do Nevro's earnings and revenue compare to its market cap? 1N7 fundamental statistics Market cap €135.83m Earnings (TTM ) -€67.53m Revenue (TTM ) €408.42m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1N7 income statement (TTM ) Revenue US$419.15m Cost of Revenue US$134.06m Gross Profit US$285.09m Other Expenses US$354.40m Earnings -US$69.31m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.85 Gross Margin 68.02% Net Profit Margin -16.54% Debt/Equity Ratio 81.2%
How did 1N7 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 05:46 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Nevro Corp. is covered by 26 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Rescott Baird null null Baird Michael Polark Baird
Show 23 more analysts 
